Third line H. pylori eradication therapy with sitafloxacin, amoxicillin and vonaprazan

Third line H. pylori eradication therapy with sitafloxacin, amoxicillin and vonaprazan - Third line H. pylori eradication therapy with sitafloxacin, amoxicillin and vonaprazan

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022235

Enrollment

100

Registered

2016-05-09

Start date

2016-05-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori-positve patients after the 2nd line eradication failure

Interventions

vonaprazan 40mg, b.i.d., amoxicillin 2.0g, q.i.d., sitafloxacin 200 mg, b.i.d.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: H. pylori-positve patients after the 2nd line H. pylori eradication therapy with informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with allergy for quinolones 2. Patients with allergy for PPIs 3. Patients with severe liver injury and/or severe renal damage 4. Pregnancy or possible pregnancy 5. Patients who were recognized as inappropriate for entry

Design outcomes

Primary

Measure	Time frame
The efficacy of H. pylori eradication	—

Secondary

Measure	Time frame
adverse events MIC of STFX,AMPC, gyaA mutation	—

Countries

Japan

Contacts

Public ContactTastuhiro Masaoka

Keio University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine

masaoka@z6.keio.jp03-5363-3790

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026